"Die Trimethylaminurie (Fischgeruchsyndrom) - Hinweise auf eine neue Therapiemöglichkeit mit Desmopressin", Aktuel Urol 2007; 38: 406-407.
Pubmed abstract : http://www.ncbi.nlm.nih.gov/pubmed/17907069?dopt=Abstract
Dr. Werner was kind enough to write for this blog a summary entitled, "English Summary and Advice for Doctors/Patients" of his original paper published last year, [Trimethylaminuria (fish-odour syndrome)-- hints for a new therapeutic option with desmopressin]. This is a case study of a young boy who presents with enuresis, was treated with desmopressin, and his mother noted that his fishy body odor temporarily completely disappeared under this therapy. Dr. Werner invites physicians, scientists, and patients that support or disprove the postulated efficacy of desmpressin upon trimethyaminuria to contact him. He asks us to use his paper for the blog because, "The wider the information is spread, the higher is the chance to get some positive or negative responses from patients". Please keep in mind this is a coincidental, anecdotal observation on one case, and Dr Werner does not recommend this as a treatment for TMAU for reasons he states below.
Here is Dr Werners English Summary and Advice for Doctors/Patients :
“Die Trimethylaminurie (Fischgeruchsyndrom) – Hinweise auf
Ein neue Therapiemöglichkeit mit Desmopressin”
English Summary and Advice for Doctors/Patients
The above mentioned article provides a case report of a child suffering from trimethylaminuria (TMAU), also called fish-odour syndrome. For other reasons (enuresis) the young boy was treated with desmopressin. His mother noticed that her son’s fishy body odour temporarily completely disappeared under this therapy. This effect could be reproduced for this patient. Based on this observation the author presented a possible molecular mechanism that might explain the effect and the simultaneously observed ineffectiveness of desmopressin against the original indication.
The article is based only on a single case that is not representative. More data and further evaluation are necessary for evidence. Therefore, the objective of this publication is to share the information with patients, practitioners, and scientists worldwide with the hope that similar observations may exist or be found. This could be the starting point for further tests and the development of a new therapeutic option.
Desmopressin (also called vasopressin, DDVAP, StimateTM, MinirinTM ) is a potent drug not approved nor registered for this indication. The adverse side effects might be higher than the possible benefit. The author (pharmacist and food chemist) is not entitled to encourage any testing or treatment in cases of TMAU and does not recommend it. This off-label use is the only responsibility of physicians and their patients.
The author appreciates any discussion and information from physicians or patients that support or disprove the postulated efficacy of desmopressin against trimethylaminuria. Please contact the author directly by e-mail:
27 May 2008
Translation into English: TMAU Hints for a new therapeutic option with Desmopressin - translation into English
links on desmopressin :
Recent FDA warning (Dec 2007) : http://www.fda.gov/CDER/DRUG/InfoSheets/HCP/desmopressinHCP.htm
Web MD article on warning : http://www.webmd.com/news/20071204/2-deaths-spur-bedwetting-drug-warning